Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: Results of a prospective, double-blind, randomized trial

Bone Marrow Transplantation

Volumn 34, Issue 11, 2004, Pages 963-968

  Walsh, T ^a   Morris, A K ^b   Holle, L M ^c   Callander, N ^a,d   Bradshaw, P ^d   Valley, A W ^e   Clark, G ^f   Freytes, C O ^a,d  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Syntaxx Communications Inc   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e Pharmacy Healthcare Solutions   (United States)

^f OSI PHARMACEUTICALS INC   (United States)

Author keywords

Granisetron; Hematopoietic stem cell transplantation; Nausea; Ondansetron; Vomiting

Indexed keywords

ANTIHISTAMINIC AGENT; APREPITANT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; ETOPOSIDE; GRANISETRON; IFOSFAMIDE; LORAZEPAM; MELPHALAN; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; PROMETHAZINE; SEROTONIN 3 ANTAGONIST; THIOTEPA; TRIAZOLAM;

ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISTRESS SYNDROME; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HICCUP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREMOR; VISUAL ANALOG SCALE;

ANTIEMETICS; DOUBLE-BLIND METHOD; FEMALE; GRANISETRON; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; NAUSEA; ONDANSETRON; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; VOMITING;

EID: 10044298251     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704714     Document Type: Article

References (24)

1. 3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000; 18: 163-173.
2. Navari R, Gandara D, Hesketh P et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1242-1248.
3. Gralla RJ, Navari RM, Hesketh PJ et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998; 16: 1568-1573.
4. Ruff P, Paska W, Goedhals L et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 1994; 51: 113-118.
5. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group for Antiemetic Research. Ann Oncol 1995; 6: 805-810.
6. Audhuy B, Cappelaere P, Martin M et al. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 1996; 32A: 807-813.
7. Hesketh P, Navari R, Grote T et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Study Group. J Clin Oncol 1996; 14: 2242-2249.
8. Aapro MS, Bertoli L, Lordick F et al. Palonosetron (PALO) is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemo-therapy (HEC). Support Care Cancer 2003; 11: 39 abstract A-17.
9. Lazarus HM, Bryson JC, Lemon E et al. Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR38032F) during multiple-day chemotherapy with cisplatin prior to autologous bone marrow transplantation. J Natl Cancer Inst 1990; 82: 1776-1778.
10. Bosi A, Guidi S, Messori A et al. Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind, randomized study. J Chemother 1993; 5: 191-196.
11. Agura ED, Brown MC, Schaffer R et al. Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant. Bone Marrow Transplant 1995; 16: 213-222.
12. Barbounis V, Koumakis G, Vassilomanolakis M et al. A phase II study of Ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. Support Care Cancer 1995; 3: 301-306.
13. Fauser AA, Russ W, Bischoff M. Oral dolasetron mesilate (MDL 73,147EF) for the control of emesis during fractionated total-body irradiation and high-dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation. Support Care Cancer 1997; 5: 219-222.
14. Frakes LA, Brehm TL, Kosty MP et al. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. Bone Marrow Transplant 1997; 20: 473-478.
15. Birch R, Weaver CH, Carson K, Buckner CD. A randomized trial of once vs twice daily administration of intravenous granisetron with dexamethasone in patients receiving high-dose cyclophosphamide, thiotepa and carboplatin. Bone Marrow Transplant 1998; 22: 685-688.
16. Osowski CL, Dix SP, Lynn M et al. An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. Support Care Cancer 1998; 6: 511-517.
17. Perez EA, Tiemeier T, Solberg LA. Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review. Support Care Cancer 1999; 7: 413-424.
18. Abbott B, Ippoliti C, Hecth D et al. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant 2000; 25 1279-1283.
19. Abang AM, Takemoto MH, Pham T et al. Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation. AntiCancer Drugs 2000; 11: 137-142.
20. Ballen KK, Hesketh AM, Heyes C et al. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant 2001; 28 1061-1066.
21. Kalaycio M, Mendez Z, Pohlman B et al. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. J Cancer Res Clin Oncol 1998; 124: 265-269.
22. Orchard PJ, Rogosheske J, Burns L et al. A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biol Blood Marrow Transplant 1999; 5: 386-393.
23. Bubalo J, Seelig F, Karbowicz S, Maziarz RT. Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 439-445.
24. Southwestern Oncology Group (SWOG) toxicity grading criteria, available from URL. http://www.fda.gov/cder/cancer/toxicityframe.htm [accessed July 29, 2003].